A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers

Inclusion Criteria: * Patients must have biopsy-proven, resected with curative intent cholangiocarcinoma, gallbladder, pancreatic or ampullary adenocarcinoma. * Patients must be 18 years or older. * Patients must have a NCI CTC Performance Status of 0-2. * Patients must not have any prior chemotherapy or radiation therapy for this current malignancy. * At least 3 weeks should have elapsed since any surgery requiring general anesthesia. * Patients must have no prior malignancies except for basal or squamous skin cancers, cervical carcinoma-in-situ, unless in remission for \>5years * Pregnant patients are not eligible. Non-pregnant status will be determined in all women of childbearing potential. All patients will be required to use an effective means of contraception if sexually active during therapy. * Initial Required Laboratory Values: * Absolute neutrophil count ≥ 1,500/mm3, platelet count ≥ 150, 000/mm3, and hemoglobin ≥ 9 g/dL. * Serum creatinine should be ≤ 2 mg/dL. * Serum bilirubin should be ≤ 3.0 mg/dL (biliary stents allowed). * Serum transaminases should be ≤ 5-fold the institutional upper limits. * Patients must not have any co-existing severe medical illnesses, such as unstable angina, uncontrolled diabetes mellitus, uncontrolled arrhythmia or uncontrolled infection. * Patients must be able to sign an informed consent. Exclusion Criteria: * None